A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a single-site, randomized, double-blind, placebo-controlled, multiple dose, flexible
dosage range, PK and PD study of SKL15508 as monotherapy in subjects with stable
schizophrenia.